SG11201811062XA - Cysteine engineered fibronectin type iii domain binding molecules - Google Patents

Cysteine engineered fibronectin type iii domain binding molecules

Info

Publication number
SG11201811062XA
SG11201811062XA SG11201811062XA SG11201811062XA SG11201811062XA SG 11201811062X A SG11201811062X A SG 11201811062XA SG 11201811062X A SG11201811062X A SG 11201811062XA SG 11201811062X A SG11201811062X A SG 11201811062XA SG 11201811062X A SG11201811062X A SG 11201811062XA
Authority
SG
Singapore
Prior art keywords
mckean
road
cysteine engineered
international
spring house
Prior art date
Application number
SG11201811062XA
Inventor
Mark Anderson
Ricardo Attar
Michael Diem
Shalom Goldberg
Linus Hyun
Steven Jacobs
Alastair King
Donna Klein
Sheri Moores
Karyn O'neil
Kristen Picha
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201811062XA publication Critical patent/SG11201811062XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) -., (19) World Intellectual Property 1111111011110111011111111010111110011111111111111110111111111111ffinill Organization International Bureau (10) International Publication Number (43) International Publication Date ......'\"' WO 2017/223180 A3 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: McKean Road, Spring House, PA 19477 (US). DIEM, A61K 38/00 (2006.01) C07K 16/28 (2006.01) Michael; 1400 McKean Road, Spring House, PA 19477 A61K 38/39 (2006.01) C12N 15/09 (2006.01) (US). GOLDBERG, Shalom; 1400 McKean Road, Spring C07K 14/78 (2006.01) House, PA 19477 (US). HYUN, Linus; 1400 McKean (21) International Application Number: Road, Spring House, PA 19477 (US). JACOBS, Steven; PCT/US2017/038506 1400 McKean Road, Spring House, PA 19477 (US). KING, Alastair; 27204 Cuivre Drive, Lake Saint Louis, MO 63367 (22) International Filing Date: (US). KLEIN, Donna; 1400 McKean Road, Spring House, 21 June 2017 (21.06.2017) PA 19477 (US). MOORES, Sheri; 1400 McKean Road, Spring House, PA 19477 (US). O'NEIL, Karyn; 1400 (25) Filing Language: English McKean Road, Spring House, PA 19477 (US). PICHA, (26) Publication Language: English Kristen; 1400 McKean Road, Spring House, PA 19477 (30) Priority Data: (US). 62/352,776 21 June 2016 (21.06.2016) US (74) Agent: SHIRTZ, Joseph, F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; (US). 800/850 Ridgeview Drive, Horsham, PA 19044 (US). (81) Designated States (unless otherwise indicated, for every (72) Inventors: ANDERSON, Mark; 8020 Fairview Lane, kind of national protection available): AE, AG, AL, AM, Eagleville, PA 19403 (US). ATTAR, Ricardo; 1400 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (54) Title: CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES = SEQ ID NO; = 18 L p7inclWivsEVTEnstl2i.,814 (60) OF - HOFY - 68FLIQYQF;SEXVGgAIALTNIPOS21 4 ,SYtTLTG EEE 1.9 LPAPKNLVVSRVTEDSLRLSW YD-RDEYDSFIJQYQ3SEKVGRAINTUVPGSERSYDIaG 20 LPAPKNLVVSEVTEDSLRLSW YN-GDHYDSELIOYQESEKVGEAINLTVPGSERSYDLTG _ 2 . 1 LPAPKNLVVSEVTEDSLRLSW DP7RGPTESPITOOSEKVGEAIWLIVPGSERSYDLT = 22 LPAPKNLVVSEVTEDSLRLSW WP-YADLDSFLIMESEKVGEAINLTVPCSEPSYDLTC = 73 1,PAPKNINvSET1MSLRLSW IN - MHEMSFLIVQ1SEKVOtaINLTV8GnRSYDLTG 24 L PAPKNLVVSEVTE D S LRL SW 7.YDLG.DHFDSEL IQYQESEKVGEAINLTVPGSERS YDLTG 2.5 LPAPKNLVVSEVTEDSLRLSW DP-WAFYESFLIQYOaSEKVGEAINLTVPGSERSYDLTG = 27 'LPAPKNLVVSEVTEDSARLS DP-WAVYESELIOYOESEKVGEAIVLTVPGSERSYDLTG = 29 LPAMINVSEVTE081Aus WP-YA0LDBFLIOYQE88XyGEAINLTI7PGSERgyaLTG 1.07 LPAPKNLVVSEVTEDSARLSW DP-HGETDSFLIQYQESEKVGEATVLTVPQSERSYDLTG = = _ 108 LPAPKNLVVSEVTEDSARLSW DP-WAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG 10.9 LPAPKNLVVSEVTEDSARLSW DP-HAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG 110 LPAPKNLVVSEVTEDSARLSW DP-HOFTDSFLIQYQESEKVGEAIVLTVPGSERSYDLTG = ..*......******* kle.* :. = - 18 LIOGT8x1V8IYOV4NVYK0TWRGLPLSAEFTT (94) - = 19 LKPGTEYTVSIYGV-INVYKDTNMRGLPLSAEFTT = 20 LKPGTEETVSIYGViNVYKDTNMPGDPLSAEFTT 21 LKPGTEYTVSIYGViNVYKDTNMAGLPISAEFTT = 22 LKPGTEYTVSIYGVSNVYKDTNMPGLPLSAEFTT _ = 2.3 VF,PGTEYTITSlyGV iNVYKIDTNIvIRGLPL8AE,FIT — 24 L.KPGTEYTVSIYGV-INVYKDTNMPOLPLSAEPTT 25 LKPGTEYTVSIYGVEINVYKDTNNRGLPLSAEETT = 27 LKPGTEYTVSIYGV - INVYKDTNMRGLPLSAIVTT 29 LKPGTEYTVSIYGViNVYKDTNMRGDPLSAEFTT 101 LEKTEXTV$IYGViNITYK0TWROLPL821InT — 108 LKPGTEYTVSIYGV-INVYKDTNIRGLPLSAIFTT 109 LXPG . TEYTv81YONNUINIOTNIROIPLSAIEIT FIG. 114 M 110 LKPGTEYTVSIYGViNVYKOTNIRGLPLSAIFTT © GC ,_ 1 (57) : Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising M one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or e• 1 more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; el ---- expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing ir---- molecule, isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a 1-1 © detection label or a drug moiety and used therapeutically. N O [Continued on next page] WO 2017/223180 A3 IMEDIMO DOI 01011MMEMODIMOIIIIHMOMMEEN CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 01 February 2018 (01.02.2018)
SG11201811062XA 2016-06-21 2017-06-21 Cysteine engineered fibronectin type iii domain binding molecules SG11201811062XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352776P 2016-06-21 2016-06-21
PCT/US2017/038506 WO2017223180A2 (en) 2016-06-21 2017-06-21 Cysteine engineered fibronectin type iii domain binding molecules

Publications (1)

Publication Number Publication Date
SG11201811062XA true SG11201811062XA (en) 2019-01-30

Family

ID=60660729

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811062XA SG11201811062XA (en) 2016-06-21 2017-06-21 Cysteine engineered fibronectin type iii domain binding molecules

Country Status (12)

Country Link
US (2) US10662235B2 (en)
EP (1) EP3471750A4 (en)
JP (1) JP2019527540A (en)
KR (1) KR20190020108A (en)
CN (1) CN109689080A (en)
AU (1) AU2017281083B2 (en)
EA (1) EA201990067A1 (en)
IL (1) IL263623A (en)
MA (1) MA45412A (en)
MX (1) MX2018016185A (en)
SG (1) SG11201811062XA (en)
WO (1) WO2017223180A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126021C2 (en) * 2016-06-03 2022-08-03 Янссен Байотек, Інк. Serum albumin-binding fibronectin type iii domains
CA3046963A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN114786682A (en) 2019-10-14 2022-07-22 Aro生物疗法公司 Fibronectin type III domain of CD71
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021127353A1 (en) * 2019-12-18 2021-06-24 Aro Biotherapeutics Company Serum albumin-binding fibronectin type iii domains and uses thereof
WO2023212704A2 (en) * 2022-04-29 2023-11-02 Tezcat Biosciences, Inc. Macropinocytosis selective non-binding protein-drug conjugates

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2118066T3 (en) 1989-10-05 1998-09-16 Optein Inc SYNTHESIS AND ISOLATION, EXEMPTED FROM CELLS, FROM NEW GENES AND POLYPEPTIDES.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5846456A (en) 1996-01-17 1998-12-08 National Science Council Method of making gradient index optical element
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (en) 2001-09-26 2010-12-22 アイシン精機株式会社 Automotive door
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
DE60335000D1 (en) 2002-09-06 2010-12-30 Isogenica Ltd IN VITRO PEPTIDE EXPRESSION BANK
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
EP2592155B2 (en) 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
RU2429014C2 (en) 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Treatments of cancer expressing mutant egf receptors
JP5926487B2 (en) 2007-04-13 2016-05-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Method for treating cancer resistant to ErbB therapy
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
US20110118144A1 (en) 2007-12-19 2011-05-19 Linus Hyun Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
CN101970730A (en) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
CA2710835A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
MX2010008874A (en) * 2008-02-14 2010-09-22 Bristol Myers Squibb Co Targeted therapeutics based on engineered proteins that bind egfr.
US20090226443A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and egfr antagonists
CL2009000843A1 (en) 2008-04-11 2009-07-24 Galaxy Biotech Llc Method of treating cancer in a patient comprising the administration of a first agent that is inhibitory of hepatocyte growth factor (hgf) in combination with a second agent that is inhibitor of a cellular signaling pathway other than the hgf / cmet pathway.
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
UY31800A (en) 2008-05-05 2009-11-10 Smithkline Beckman Corp CANCER TREATMENT METHOD USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR
AR071874A1 (en) * 2008-05-22 2010-07-21 Bristol Myers Squibb Co ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CA2741834C (en) 2008-10-31 2022-04-05 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
PA8849001A1 (en) 2008-11-21 2010-06-28 Lilly Co Eli C-MET ANTIBODIES
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
MX2011010169A (en) 2009-04-07 2011-10-11 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies.
WO2011100700A2 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
CN103003307B (en) 2010-03-10 2017-08-11 根马布股份公司 Anti- c MEt monoclonal antibody
MX341119B (en) 2010-04-13 2016-08-09 Medimmune Llc Trail r2-specific multimeric scaffolds.
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
ES2617777T5 (en) 2010-04-23 2022-10-13 Hoffmann La Roche Production of heteromultimeric proteins
AU2011245225B2 (en) 2010-04-30 2015-09-17 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
ES2573108T3 (en) * 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Fibronectin-based framework proteins that have improved stability
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20240005211A (en) * 2012-11-21 2024-01-11 얀센 바이오테크 인코포레이티드 BISPECIFIC EGFR/c-Met ANTIBODIES
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
AU2014334627B2 (en) * 2013-10-14 2019-07-25 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
UA126021C2 (en) * 2016-06-03 2022-08-03 Янссен Байотек, Інк. Serum albumin-binding fibronectin type iii domains

Also Published As

Publication number Publication date
IL263623A (en) 2019-01-31
US20170362301A1 (en) 2017-12-21
EP3471750A4 (en) 2020-02-26
AU2017281083B2 (en) 2022-01-27
WO2017223180A3 (en) 2018-02-01
WO2017223180A2 (en) 2017-12-28
US20200325210A1 (en) 2020-10-15
KR20190020108A (en) 2019-02-27
EA201990067A1 (en) 2019-07-31
US10662235B2 (en) 2020-05-26
EP3471750A2 (en) 2019-04-24
MX2018016185A (en) 2019-03-28
JP2019527540A (en) 2019-10-03
AU2017281083A1 (en) 2019-01-24
MA45412A (en) 2021-05-26
CN109689080A (en) 2019-04-26

Similar Documents

Publication Publication Date Title
SG11201811062XA (en) Cysteine engineered fibronectin type iii domain binding molecules
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201811600PA (en) Pseudotyped oncolytic viral delivery of therapeutic polypeptides
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201900907YA (en) Adenosine nucleobase editors and uses thereof
SG11201908012SA (en) Cyclic sulfamide compounds and methods of using same
SG11201808014SA (en) Compositions, devices, and methods for cell separation
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901066UA (en) Novel alkaline stable immunoglobulin-binding proteins
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201906341XA (en) Improved serum albumin binders
SG11201806398YA (en) Optimized factor viii genes
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201907769XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use